Karine Tawagi: Expert panel BCANTT24 on the future of IO in Bladder Cancer
Karine Tawagi, University of Illinois Chicago, shared a post on X:
“Expert panel BCANTT24 on the future of IO in Bladder Cancer:
- key ongoing trials w/ recent NIAGARA read-out.
- lack biomarkers of response & resistance, PDL1 is not it.
- need de-escalation as many pt advocates expressed this meeting inc consolidation for CR in mUC, IO post IO.“
Source: Karine Tawagi/X
Read about BCANTT24: The annual BCAN Bladder Cancer Think Tank Meeting is the premier annual bladder cancer-specific medical meeting in North America. Think Tank fosters innovation and collaboration among individuals from the medical, research, and patient communities. Its objective is to accelerate advancements in diagnosing, treating, and enhancing the quality of life for those affected by bladder cancer.
Since its establishment in 2006, the Think Tank meeting has focused on identifying obstacles and creating solutions in bladder cancer research, and has fostered discussions to help define priorities for advancing bladder cancer research.
The invited participants comprise urologists, oncologists, researchers, pathologists, social scientists, patient advocates, and industry representatives, all committed to advancing the diagnosis and treatment of bladder cancer.